| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 9th February 2021 | Capital Management, L.P. Ra | 2,848,596 | Open or private purchase | $18.00 | $51,274,728.00 |
| 9th February 2021 | Capital Management, L.P. Ra | 1,664,549 | Conversion of derivative | $0.00 | |
| 9th February 2021 | Capital Management, L.P. Ra | 280,330 | Conversion of derivative | $0.00 | |
| 9th February 2021 | Capital Management, L.P. Ra | 130,970 | Open or private purchase | $18.00 | $2,357,460.00 |
| 9th February 2021 | Capital Management, L.P. Ra | 3,784,120 | Conversion of derivative | $0.00 | |
| 9th February 2021 | Capital Management, L.P. Ra | 1,414,026 | Conversion of derivative | $0.00 | |
| 4th February 2021 | Capital Management, L.P. Ra | 11,651,597 | Conversion of derivative | $0.00 | |
| 6th January 2021 | Frank Neumann | 150,000 | Grant/award etc. | $0.00 | |
| 18th December 2020 | Dan Paterson | 135,851 | Grant/award etc. | $0.00 | |
| 18th December 2020 | Brian M Stuglik | 203,776 | Grant/award etc. | $0.00 |
Verastem
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.
Verastem, Inc. is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K)
Ticker: VSTM
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1526119
Employees: 169
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
Restructuring Charges of $0 for the period Jan 2020 to Jun 2020 in the context of One time termination benefits
Restructuring Charges of $2 M for the period Jan 2020 to Jun 2020 in the context of One time termination benefits
Fundamentals
Cash at Carrying Value: $125 M (0%)
Inventory, Net: $6 M (0%)
Assets, Current: $145 M (70%)
Property, Plant and Equipment, Net: $791 Th (-16%)
Other Assets, Noncurrent: $401 Th (-50%)
Assets: $199 M (36%)
Accounts Payable, Current: $2 M (-76%)
Accrued Liabilities, Current: $21 M (0%)
Liabilities, Current: $29 M (-3%)
Other Liabilities, Noncurrent: $870 Th (0%)
Liabilities: $84 M (-38%)
Common Stock, Value, Issued: $17 Th (112%)
Common Stock, Shares, Issued: $169 M (211260%)
Additional Paid in Capital, Common Stock: $700 M (31%)
Retained Earnings (Accumulated Deficit): $586 M (0%)
Stockholders' Equity (Parent): $114 M (0%)
Liabilities and Equity: $199 M (36%)
Revenue: $4 M (-53%)
Research and Development: $9 M (-53%)
Operating Income/Loss: $21 M (-55%)
News
Verastem: Revisiting This $2 Oncology Concern
27th December 2020